## Aurobindo Pharma Limited (AUROPHARMA) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Aurobindo Pharma Limited (AUROPHARMA) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) since July 19, 2000.  It operates within the Pharmaceuticals & Biotechnology industry and holds a significant position in the Indian pharmaceutical market, known for its generic drug manufacturing and marketing.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,241.00       | Closed at ₹1,241.70, down ₹13.70 (-1.09%) from the previous close. |
| Percentage Change (PChange) | -1.09%          | Negative daily price movement.                                      |
| Pre-Open Activity          | ₹1,254.80       |  Slight increase from previous close during pre-open session.       |
| Week High                    | ₹1,592.00       | High reached on September 13, 2024.                               |
| Week Low                     | ₹958.50        | Low reached on February 14, 2024.                                |
| VWAP                        | ₹1,261.43       | Volume Weighted Average Price.                                       |
| Sector PE                   | 19.88           | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 20.25           | Price-to-Earnings ratio for AUROPHARMA.                            |
| Delivery Percentage         | 57.26%          | Relatively high delivery percentage suggests some degree of conviction. |
| Market Depth                | Low              | Order book data shows low market depth, indicating potential volatility.|


**3. Financial Performance:**

The following table summarizes Aurobindo Pharma's financial performance over the past five quarters.  Note that the data provided includes both audited and unaudited figures.  Profit After Tax (PAT) and Earnings Per Share (EPS) are consistently positive, indicating profitability. However, there is a notable decline in profitability in the most recent quarter.

| Quarter Ending      | Revenue (₹ in millions) | Expenses (₹ in millions) | PAT (₹ in millions) | Diluted EPS (₹) |
|----------------------|--------------------------|--------------------------|----------------------|-----------------|
| 30-Sep-2024 (U)      | 294,725                  | 222,350                  | 53,753                | 9.21             |
| 30-Jun-2024 (U)      | 252,541                  | 207,917                  | 32,904                | 5.62             |
| 31-Mar-2024 (A)      | 301,700                  | 223,712                  | 57,867                | 9.88             |
| 31-Dec-2023 (U)      | 302,316                  | 233,594                  | 62,378                | 10.65            |
| 30-Sep-2023 (U)      | 273,584                  | 222,606                  | 41,574                | 6.48             |

**(U) - Unaudited; (A) - Audited**

**Key Financial Ratios:**  Further analysis requires more detailed financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc.  The provided data only allows for a limited assessment.

**4. Corporate Actions and Announcements:**

Aurobindo Pharma has undertaken several corporate actions recently, including interim dividends and an AGM.  A significant event was the buyback of shares in July 2024.  Recent announcements include press releases and updates regarding share certificates.  The frequency of announcements suggests active corporate communication.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|-----------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023     | 51.83                        | 48.17      | 0.00                | 100.00    |
| 31-Dec-2023     | 51.83                        | 48.17      | 0.00                | 100.00    |
| 31-Mar-2024     | 51.83                        | 48.17      | 0.00                | 100.00    |
| 30-Jun-2024     | 51.80                        | 48.20      | 0.00                | 100.00    |
| 30-Sep-2024     | 51.82                        | 48.18      | 0.00                | 100.00    |

Promoter holding remains relatively stable over the period.

**6. Volatility and Risk Assessment:**

The week's high and low prices (₹1,592.00 and ₹958.50 respectively) indicate significant price volatility.  The CM Annual Volatility of 32.67% further confirms this high risk profile.  The low market depth adds to the risk, suggesting that large trades could significantly impact the price.

**7. Advantages of Buying the Stock:**

* **Consistent Profitability:** Aurobindo Pharma has shown consistent profitability over the past five quarters.
* **Established Player:** It's a well-established player in the pharmaceutical sector.
* **Dividend Payments:** The company has a history of paying dividends.

**8. Disadvantages and Risks:**

* **High Volatility:** The stock exhibits significant price volatility.
* **Declining Profitability:**  A recent decline in profitability is a cause for concern.
* **Market Dependence:** The pharmaceutical sector is susceptible to regulatory changes and market fluctuations.
* **Low Market Depth:**  This increases the risk of sharp price movements.


**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Hold.** The recent price decline and low market depth suggest caution.  Waiting for clearer price direction is advisable.

* **Medium-Term (3 to 12 months): Hold.**  Monitor financial performance and industry trends closely.  The buyback could provide some support, but volatility remains a concern.

* **Long-Term (1 year and beyond): Hold.**  Aurobindo Pharma's fundamentals are relatively strong, but the high volatility necessitates a long-term perspective to ride out market fluctuations.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* **Financial Health (out of 10): 7**  Consistent profitability, but recent decline needs monitoring.
* **Market Performance (out of 10): 5**  High volatility and recent price drop.
* **Volatility and Risk (out of 10): 4**  High volatility and low market depth are significant risks.
* **Corporate Actions & Governance (out of 10): 8**  Active corporate communication and regular dividend payments.
* **Shareholding Patterns (out of 10): 7**  Stable promoter holding.

**Analysis Score (out of 10): 9**

* **Data Utilization (out of 10): 10**  All provided data was used in the analysis.
* **Accuracy & Clarity (out of 10): 9**  Analysis is clear and well-structured, but some limitations due to incomplete financial data.
* **Professional Formatting (out of 10): 9**  Report is well-formatted and easy to read.


**11. Professional Recommendation Summary:**

Aurobindo Pharma presents a mixed picture. While its fundamentals are relatively strong, the high volatility and recent decline in profitability warrant a cautious approach.  A "Hold" recommendation is given across all investment horizons, with close monitoring of financial performance and market conditions crucial for future investment decisions.  Further analysis with complete financial statements would allow for a more comprehensive evaluation.
